- Patients who are considered ineligible for surgery, or any other treatment, who are progressing following loco-regional therapy and/or sorafenib Patients who are naïve to sorafenib are eligible to participate to the study when investigator consider using sorafenib is not suitable for subject after evaluating the risk/ benefit or subject is reluctant to use sorafenib.